telmisartan has been researched along with Carcinoma, Renal Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, SS; Kim, HJ; Kwon, YJ; Suh, GH | 1 |
| Arlot-Bonnemains, Y; Belaud-Rotureau, MA; Bensalah, K; Collet, N; Dolley-Hitze, T; Jouan, F; Lavenu, A; Oger, E; Rioux-Leclercq, N; Verhoest, G; Vigneau, C | 1 |
2 other study(ies) available for telmisartan and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Successful management of proteinuria and systemic hypertension in a dog with renal cell carcinoma with surgery, telmisartan, and amlodipine.
Topics: Amlodipine; Animals; Antihypertensive Agents; Carcinoma, Renal Cell; Dog Diseases; Dogs; Hypertension; Kidney Neoplasms; Male; Nephroureterectomy; Proteinuria; Telmisartan | 2018 |
Sunitinib combined with angiotensin-2 type-1 receptor antagonists induces more necrosis: a murine xenograft model of renal cell carcinoma.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Benzoates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Pyrroles; Sunitinib; Telmisartan; Xenograft Model Antitumor Assays | 2014 |